NKMAX’s specialized technique, stable-peptide fusion technology, was designed for proteins that are susceptible to external environment or need to be stored for long-term or in room temperature.
Based on the core SP fusion technology (Stable peptide), NKMAX manufacture and ship a substantial list of recombinant proteins and monoclonal antibodies world widely.
This is an innovative technology patented by NKMAX for stabilizing fusion protein to make proteins more resistant to damage from their environment.
(Patent No. 1005067660000 PEPTIDES CONFERRING ENVIRONMENTAL STRESS RESISTANCE AND FUSION PROTEINS CONTAINING THE SAME)
Having acquired expertise with fusion peptides, NKMAX has developed over 4,400 high quality recombinant proteins and over 400 monoclonal antibodies, which are being sold in over 40 countries around the world.
NKMAX’s recombinant proteins are produced using different expression systems such as E.coli, insect cells, and animal cells from a large and diversified DNA library. To develop better monoclonal antibodies, NKMAX uses bioinformatics, specialized techniques, and high QC standard.
NKMAX has positioned itself as a world-leading manufacturer of research reagents through its unique technology and continuous R&D. NKMAX hopes to bring innovative solutions to the global bio research industry.
For more details, please visit our website www.nkmaxbio.com for research reagents.